News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,068 Results
Type
Article (13817)
Company Profile (101)
Press Release (252150)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88073)
Career Advice (465)
Deals (15347)
Drug Delivery (67)
Drug Development (36607)
Employer Resources (49)
FDA (6299)
Job Trends (6202)
News (150262)
Policy (14045)
Tag
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (36)
Alliances (23238)
ALS (37)
Alzheimer's disease (394)
Antibody-drug conjugate (ADC) (42)
Approvals (6339)
Artificial intelligence (112)
Autoimmune disease (9)
Automation (4)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (22)
Brain cancer (16)
Breast cancer (83)
Cancer (645)
Cardiovascular disease (72)
Career advice (409)
Career pathing (12)
CAR-T (23)
Cell therapy (90)
Cervical cancer (4)
Clinical research (30945)
Collaboration (352)
Compensation (157)
Complete response letters (17)
COVID-19 (759)
CRISPR (22)
C-suite (128)
Cystic fibrosis (37)
Data (666)
Denatured (15)
Depression (10)
Diabetes (83)
Diagnostics (1325)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (66)
Drug shortages (12)
Duchenne muscular dystrophy (37)
Earnings (32228)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37599)
Executive appointments (400)
FDA (6740)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (216)
Gene editing (40)
Generative AI (9)
Gene therapy (101)
GLP-1 (350)
Government (1301)
Grass and pollen (3)
Guidances (22)
Healthcare (3565)
Huntington's disease (4)
IgA nephropathy (12)
Immunology and inflammation (35)
Indications (14)
Infectious disease (794)
Inflammatory bowel disease (56)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (48)
Interviews (59)
IPO (5880)
IRA (29)
Job creations (2051)
Job search strategy (373)
Kidney cancer (6)
Labor market (12)
Layoffs (181)
Leadership (4)
Legal (3433)
Liver cancer (19)
Lung cancer (87)
Lymphoma (57)
Machine learning (2)
Management (16)
Manufacturing (162)
MASH (34)
Medical device (1277)
Medtech (1279)
Mergers & acquisitions (9677)
Metabolic disorders (266)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (8)
Neuroscience (584)
NextGen: Class of 2025 (1588)
Non-profit (596)
Now hiring (8)
Obesity (151)
Opinion (119)
Ovarian cancer (22)
Pain (54)
Pancreatic cancer (15)
Parkinson's disease (47)
Partnered (7)
Patents (121)
Patient recruitment (30)
Peanut (10)
People (28992)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8055)
Phase II (13092)
Phase III (11747)
Pipeline (470)
Policy (72)
Postmarket research (1401)
Preclinical (3230)
Press Release (25)
Prostate cancer (48)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (170)
Real estate (2637)
Recruiting (17)
Regulatory (10141)
Reports (14)
Research institute (566)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (38)
Series B (13)
Service/supplier (3)
Sickle cell disease (32)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1629)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (31)
The Weekly (30)
Vaccines (156)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (4)
Date
Today (65)
Last 7 days (273)
Last 30 days (902)
Last 365 days (11758)
2025 (3911)
2024 (12505)
2023 (14247)
2022 (19556)
2021 (20070)
2020 (19032)
2019 (14886)
2018 (11714)
2017 (13890)
2016 (13130)
2015 (15473)
2014 (12421)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10890)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (57)
Arkansas (3)
Asia (20150)
Australia (2616)
California (1784)
Canada (930)
China (248)
Colorado (71)
Connecticut (70)
Delaware (60)
Europe (39522)
Florida (341)
Georgia (39)
Idaho (9)
Illinois (202)
India (16)
Indiana (137)
Iowa (1)
Japan (96)
Kansas (58)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (264)
Massachusetts (1535)
Michigan (30)
Minnesota (95)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (786)
New Mexico (7)
New York (533)
North Carolina (403)
North Dakota (2)
Northern California (734)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (460)
Puerto Rico (8)
Rhode Island (10)
South America (502)
South Carolina (2)
Southern California (748)
Tennessee (34)
Texas (237)
United States (7454)
Utah (34)
Virginia (78)
Washington D.C. (31)
Washington State (123)
Wisconsin (17)
266,068 Results for "kleo pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the “Company” or “Biohaven”) today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. (“Kleo”) that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab
January 7, 2021
·
8 min read
Pharm Country
Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab
Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, is presenting preclinical data today on KPMW135, a novel CD3 x CD20 bispecific molecule developed with Kleo’s multi-targeted antibody therapy enhancer (MATE™) conjugation platform.
December 7, 2020
·
3 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
Mergers & acquisitions
Taiho Pharmaceutical Buys ADC Partner Araris for up to $1.1B Total
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.
March 17, 2025
·
2 min read
·
Dan Samorodnitsky
Pharm Country
Kleo Pharmaceuticals to Present at “Bioscience Pipeline & Innovation in Connecticut in the Age of COVID” Conference
Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present today to local stakeholders at the Bioscience Pipeline & Innovation in Connecticut in the Age of COVID conference on Monday, September 21, 2020 at 2:00 p.m. ET
September 21, 2020
·
2 min read
Pharm Country
Kleo Pharmaceuticals to Present at the LifeSci Partners Summer Symposium
Kleo Pharmaceuticals announced today that Doug Manion, MD, Chief Executive Officer and Chairman of the Board, will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020. Please click the following link to register: https://lifesci.events/SummerSymposium . Presentation Details: Date: August 5, 2020 Time: 8:30am Eastern Time About Kl
July 29, 2020
·
1 min read
Business
Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board
Kleo is a novel immuno-oncology company spun out of Yale University developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics
November 4, 2019
·
5 min read
Pharm Country
Kleo Pharmaceuticals to Present at Biotech Showcase 2020
Kleo Pharmaceuticals, Inc. announced that its Chief Executive Officer Doug Manion, MD, will present at Biotech Showcase 2020, to be held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco.
December 18, 2019
·
3 min read
Press Releases
X4 Pharmaceuticals Announces Reverse Stock Split
April 24, 2025
·
6 min read
Business
United Spinal Appoints Kleo J. King As Senior Director of Accessibility Operations & Counsel
United Spinal Association has announced the appointment of Kleo J. King, a legal advisor and attorney specializing in accessible housing, transportation, and public accommodations, as Senior Director of Accessibility Operations and Counsel.
March 12, 2021
·
2 min read
1 of 26,607
Next